Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and BL) * Any stage disease * Newly diagnosed disease * Meets 1 of the following criteria for disease risk: * Low-risk disease, defined by 1 of the following: * Stage I with a single focus of disease \< 10 cm AND normal lactate dehydrogenase (LDH) level * Totally resected intra-abdominal disease only AND normal LDH post surgery * High-risk disease, defined as not meeting criteria for low-risk disease * Measurable or nonmeasurable disease * HIV-positive confirmed by enzyme-linked immunosorbent assay and Western blot OR by measurable HIV viral load * No visceral Kaposi's sarcoma PATIENT CHARACTERISTICS: * Karnofsky performance status 40-100% * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * LVEF ≥ 50% by MUGA or echocardiogram * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count ≥ 50,000/mm³ (unless related to lymphoma)\* * Direct bilirubin ≤ 2.0 mg/dL OR total bilirubin ≤ 3.5 mg/dL AND direct bilirubin normal (if elevated bilirubin secondary to antiretroviral therapy) * AST and ALT ≤ 3 times upper limit of normal * No other malignancy within the past 5 years except curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in…